Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vir Biotechnology, Inc. < Previous 1 2 Next > Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting November 15, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update October 31, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 October 17, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024 October 15, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference October 03, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers September 09, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference August 22, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities August 01, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers August 01, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 July 18, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection June 26, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment June 05, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference May 29, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer May 29, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Host 2024 Annual Meeting of Stockholders May 23, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 May 22, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 May 21, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results May 02, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 April 30, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors April 18, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 April 11, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule March 05, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences February 23, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results February 22, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer February 20, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 February 01, 2024 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation December 13, 2023 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference December 06, 2023 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023 November 13, 2023 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023 November 10, 2023 From Vir Biotechnology, Inc. Via Business Wire Tickers VIR < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
